Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma

Basit Öğe Kaydı
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.contributor.authorKuku, I
dc.contributor.authorBayraktar, MR
dc.contributor.authorKaya, E
dc.contributor.authorErkurt, MA
dc.contributor.authorBayraktar, N
dc.contributor.authorCikim, K
dc.contributor.authorAydogdu, I
dc.date.accessioned2024-08-04T20:15:02Z
dc.date.available2024-08-04T20:15:02Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractMultiple myeloma (MM) is a malignant disease characterized by the clonal proliferation of plasma cells within the bone marrow. Several cytokines have been demonstrated to be involved in the control of growth, progression, and dissemination of MM. We determined serum levels of interleukin-1 beta (IL- 1 beta), Soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) in 14 newly diagnosed MM patients. The median age of the patients was 63.4 +/- 10.8 years and all of the patients were stage III (classified according to the Durie-Salmon classification). The same parameters were measured in 15 healthy controls. In addition, we also examined the effects of vincristine-adriamycin-dexamethasone (VAD) therapy on the same parameters and mediators as well as the relationship among the parameters in the same patient groups. The serum concentrations of TNF-alpha, IL-1 beta, sIL-2R, I L-6, IL-8, and CRP (18.6 +/- 3.7 pg/mL, 10.1 +/- 2.8 pg/mL, 730 +/- 220 U/mL, 11.4 +/- 3.3 pg/mL, 23.9 +/- 8.3 pg/mL, and 49.9 +/- 19.5 mg/dL, resp) were significantly higher in newly diagnosed MM patients than ill healthy controls (P <.0001). All of the parameters were found to be significantly reduced after chemotherapy. In conclusion, we found that after the VAD therapy, the level of these cytokines which are thought to play an important role in the pathogenesis of MM was significantly suppressed. This is the first study demonstrating strong impact of VAD treatment on circulating mediators of sIL-2R and IL-8 levels parameters.en_US
dc.identifier.doi10.1155/MI.2005.171
dc.identifier.endpage174en_US
dc.identifier.issn0962-9351
dc.identifier.issue3en_US
dc.identifier.pmid16106104en_US
dc.identifier.scopus2-s2.0-25644440577en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage171en_US
dc.identifier.urihttps://doi.org/10.1155/MI.2005.171
dc.identifier.urihttps://hdl.handle.net/11616/94116
dc.identifier.wosWOS:000233338200008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHindawi Publishing Corporationen_US
dc.relation.ispartofMediators of Inflammationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMalignant Plasma-Cellsen_US
dc.subjectPhase Protein-Levelsen_US
dc.subjectHigh-Dose Therapyen_US
dc.subjectBone-Diseaseen_US
dc.subjectInterleukin-6en_US
dc.subjectCanceren_US
dc.subjectCytokinesen_US
dc.subjectAngiogenesisen_US
dc.subjectExpressionen_US
dc.subjectChemokinesen_US
dc.titleSerum proinflammatory mediators at different periods of therapy in patients with multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu